MX9700413A - Inhibidores de proteina fijadora de factor liberador de corticotropina y su uso. - Google Patents
Inhibidores de proteina fijadora de factor liberador de corticotropina y su uso.Info
- Publication number
- MX9700413A MX9700413A MX9700413A MX9700413A MX9700413A MX 9700413 A MX9700413 A MX 9700413A MX 9700413 A MX9700413 A MX 9700413A MX 9700413 A MX9700413 A MX 9700413A MX 9700413 A MX9700413 A MX 9700413A
- Authority
- MX
- Mexico
- Prior art keywords
- crf
- ligand inhibitor
- corticotropin
- administration
- releasing factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se incrementan los niveles de factor liberador de corticotropina libre (CRF) en el cerebro, mediante la administracion CRF/proteína fijadora de CRF, provocando la liberacion de CRF. El inhibidor de ligando puede ser un péptido derivado a partir de CRF, o una proteína relacionada, o un no péptido. La administracion del inhibidor de ligando puede proporcionar una mejora en el aprendizaje y la memoria, dando como resultado una ingestion de alimento disminuida, o proporcionar un tratamiento para enfermedades asociadas con bajos niveles de CRF en el cerebro, notablemente la enfermedad de Alzheimer. También se proporciona un método para rastrear compuestos para seleccionar antagonistas de CRF particularmente efectivos para su administracion en vivo a mamíferos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27624094A | 1994-07-15 | 1994-07-15 | |
| US48477695A | 1995-06-07 | 1995-06-07 | |
| PCT/US1995/008867 WO1996002569A1 (en) | 1994-07-15 | 1995-07-14 | Corticotropin-releasing factor-binding-protein inhibitors and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX9700413A true MX9700413A (es) | 1998-05-31 |
Family
ID=26957870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX9700413A MX9700413A (es) | 1994-07-15 | 1995-07-14 | Inhibidores de proteina fijadora de factor liberador de corticotropina y su uso. |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0771323A1 (es) |
| JP (2) | JPH10503187A (es) |
| CN (1) | CN1157620A (es) |
| AU (1) | AU705984B2 (es) |
| CA (1) | CA2195197A1 (es) |
| MX (1) | MX9700413A (es) |
| NO (1) | NO970165L (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107058237A (zh) * | 2016-12-07 | 2017-08-18 | 陈锋 | 杂交瘤细胞株及基于杂交瘤细胞株的抗crh抗体c‑d17及其检测方面的应用 |
| CN107043752A (zh) * | 2016-12-07 | 2017-08-15 | 陈锋 | 杂交瘤细胞株及基于杂交瘤细胞株的抗crh抗体n‑d19及其检测方面的应用 |
| KR20240023691A (ko) * | 2020-08-12 | 2024-02-22 | 스프루스 바이오사이언시스 인코포레이티드 | 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4908352A (en) * | 1987-09-28 | 1990-03-13 | The Salk Institute For Biological Studies | Urotensin peptides |
| US5464757A (en) * | 1991-01-15 | 1995-11-07 | The Salk Institute For Biological Studies | DNA encoding CRF binding protein |
-
1995
- 1995-07-14 CN CN95194716A patent/CN1157620A/zh active Pending
- 1995-07-14 CA CA002195197A patent/CA2195197A1/en not_active Abandoned
- 1995-07-14 AU AU31283/95A patent/AU705984B2/en not_active Ceased
- 1995-07-14 MX MX9700413A patent/MX9700413A/es unknown
- 1995-07-14 EP EP95927176A patent/EP0771323A1/en not_active Withdrawn
- 1995-07-14 JP JP8505177A patent/JPH10503187A/ja active Pending
-
1997
- 1997-01-14 NO NO970165A patent/NO970165L/no not_active Application Discontinuation
-
2001
- 2001-04-18 JP JP2001120416A patent/JP2001348400A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN1157620A (zh) | 1997-08-20 |
| NO970165L (no) | 1997-03-14 |
| EP0771323A1 (en) | 1997-05-07 |
| AU3128395A (en) | 1996-02-16 |
| AU705984B2 (en) | 1999-06-03 |
| JPH10503187A (ja) | 1998-03-24 |
| JP2001348400A (ja) | 2001-12-18 |
| CA2195197A1 (en) | 1996-02-01 |
| NO970165D0 (no) | 1997-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ504026A (en) | Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C | |
| ATE266417T1 (de) | Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien | |
| ES2170104T3 (es) | Inhibidores de la produccion de proteinas de beta-amiloide. | |
| DE69630479D1 (de) | Arzneimittel zur Behandlung von entzündlichen Herzkrankheiten | |
| DE59711321D1 (de) | Neue substituierte pyrazolderivate zur behandlung von herzkreislauferkrankungen | |
| DE10199020I2 (de) | Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit. | |
| DE69521796D1 (de) | Behandlung des partiellen wachstumshormon-unempfindlichkeitssyndromes | |
| ATE262336T1 (de) | Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen | |
| ATE230757T1 (de) | Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten | |
| DE69636343D1 (de) | Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen | |
| MY102806A (en) | Human interleukin-3 and muteins thereof | |
| DE69631478D1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
| ATE203907T1 (de) | Dermatologische zubereitung zur behandlung von aktinischen keratosen | |
| DE69719754D1 (de) | Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung | |
| ATE294236T1 (de) | Promotor der tie rezeptor protein kinase | |
| ATE119770T1 (de) | Verwendung von acetyl l-carnitin zur therapeutischen behandlung von coma. | |
| MX9700413A (es) | Inhibidores de proteina fijadora de factor liberador de corticotropina y su uso. | |
| DE69533311D1 (de) | Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen | |
| DE69822297D1 (de) | Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten | |
| GR3034035T3 (en) | A process for the preparation of factor ix from biological sources | |
| DE69837271D1 (de) | Mutanten des thyroid-stimulierenden hormons | |
| KR950016720A (ko) | 아밀로이드 단백질의 효과를 저해하는 방법 | |
| ATE249837T1 (de) | Caspase 8-inhibitoren zur immunsuppression | |
| DE69213660D1 (de) | Verwendung von 1-(beta-d-arabinofuranosyl)-5-propynyluracil zur senkung des serumcholesterins | |
| DE59609977D1 (de) | Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern |